How Does Procaps Group Company Work?

How is Procaps Group reshaping pharma manufacturing?

Procaps Group reached a production capacity exceeding 13 billion capsules annually by early 2025, operating across 50+ countries with over 5,000 employees. Its vertical integration and CDMO capabilities position it among the top global softgel makers.

Procaps combines advanced drug delivery IP, large-scale softgel and capsule manufacturing, and CDMO services to serve pharma and nutraceutical clients globally, driving projected 2025 revenues above $470 million.

How Does Procaps Group Company Work? It integrates R&D, formulation, and contract manufacturing to offer turnkey solutions—see strategic analysis: Procaps Group Porter's Five Forces Analysis

Procaps Group operates a vertically integrated model combining R&D, large-scale manufacturing and multi-channel distribution to deliver advanced delivery systems, nutraceuticals and finished pharmaceuticals across Latin America and the US.

Vertical integration

The company controls discovery, formulation, softgel encapsulation and packaging, enabling tighter quality control and faster commercialization timelines for partners.

Proprietary delivery tech

Technologies like Unigel and Funtrition improve bioavailability and adherence by combining multiple actives or creating palatable nutraceutical gummies for consumers.

Manufacturing footprint

Operations run across 13 high-tech facilities including Barranquilla plus sites in Brazil, El Salvador and the US, supporting large-scale pharmaceutical manufacturing Procaps activities.

Distribution and logistics

A hub-and-spoke distribution model provides agility and rapid market penetration across Central and South America, optimizing inventory and lead times.

Procaps Group functions both as a branded manufacturer and a CDMO, offering end-to-end services under Nextgel that span molecule stabilization to final commercial packaging while meeting regulatory standards.

Nextgel CDMO & value proposition

Nextgel delivers turnkey contract manufacturing services explained via an integrated workflow that reduces time-to-market and unit costs for partners.

• Full-service CDMO from formulation to commercial packaging
• Regulatory approvals including FDA and INVIMA validations
• Scalable softgel technology Procaps uses to combine multiple actives
• Serves pharma customers, healthcare providers and retail consumers

Key metrics: the company’s 13 plants support multi-format output; proprietary platforms raise bioavailability and adherence; regulatory validations underpin quality control procedures and global presence and logistics across Latin America and the US enable regional market scale.

Further reading: Growth Strategy of Procaps Group

Complete Procaps Group Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Revenue Streams and Monetization Strategies of Procaps Group center on four core segments that create a diversified income mix, combining long-term manufacturing contracts, branded pharmaceutical sales, regional distribution and integrated digital-health offerings to build recurring revenue and geographic expansion.

Nextgel B2B Manufacturing

The Nextgel B2B segment contributed approximately 35% of 2025 revenue via contract manufacturing and licensing of proprietary softgel technology.

Procaps Colombia — Branded Pharmaceuticals

Procaps Colombia generated about 30% of total revenue in 2025 from prescription and OTC sales, maintaining leading national market share.

Regional CAN and CAS Segments

CAN and CAS regional operations supply hospitals, pharmacies and distributors across Central, Andean and South America, accounting for a meaningful portion of the remaining revenue mix.

Diabetrics — Integrated Diabetes Care

Diabetrics blends product sales with digital monitoring and care management, creating recurring subscription-style revenue streams beyond one-time drug purchases.

High-Margin Specialized Products

Focus on plant-based softgels (Versagel) and personalized nutrition increased gross margins in 2025, shifting monetization toward premium, differentiated SKUs.

US Expansion and Facility Growth

US-based revenue is targeted at 18% of total mix by end-2025, led by capacity expansion at the West Palm Beach facility and US-facing contract wins.

Key monetization tactics combine IP licensing, long-term CMOs, branded product margins and digital service subscriptions that leverage Procaps Group operations to increase lifetime customer value.

Primary Revenue Drivers & KPIs

Revenue composition, margin levers and recurring models to monitor for valuation and partnership decisions.

• Contract manufacturing and licensing: stable, long-term revenue with predictable backlog and renewal rates
• Branded pharmaceuticals: high ASPs and market share in Colombia driving ~30% of revenue
• Digital health integration: Diabetrics increases ARPU via subscription and remote monitoring services
• Product mix optimization: premium softgels and personalized nutrition lift gross margins and reduce commoditization risk

For further reading on commercialization and market positioning, see Marketing Strategy of Procaps Group.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Procaps Group's trajectory features strategic pivots: the 2021 NASDAQ listing funded rapid international expansion, a 2024 governance and reporting overhaul restored investor confidence, and the 2025 launch of an advanced biologicals manufacturing line moved the company into biosimilars and high-value biologics.

Key Milestones

NASDAQ listing in 2021 enabled capital for acquisitions and capacity build-out. 2024 reforms improved transparency and financial controls, reducing audit adjustments and stabilizing liquidity.

Strategic Moves

Acquisition-led expansion targeted Latin America and Europe; 2025 biologicals line diversified offerings beyond softgels into biosimilars and high-margin biologics manufacturing.

Technology & IP

IP portfolio exceeds 500 active formulations and includes dozens of patents around iCaps and ChewyGel platforms, underpinning product differentiation and licensing potential.

Financial & Operational Strength

High-volume scale delivers pricing leverage and supports industry-competitive EBITDA margins in the 18 to 22 percent range, with regional regulatory expertise reducing market entry risks.

Procaps Group operations combine contract manufacturing, proprietary drug-delivery platforms, and regional distribution networks to serve pharmaceutical partners across LATAM, Europe, and select global markets.

Competitive Edge

Competitive advantages rest on proprietary softgel technology, scale economics, regulatory know-how in Latin America, and recent vertical expansion into biologics production that raises entry barriers for peers.

• Extensive IP: > 500 formulations and multiple platform patents
• Economies of scale: production volumes enabling cost leadership and sustained EBITDA margins
• Regulatory depth: localized approvals and distribution pathways across LATAM
• Portfolio diversification: move from softgels to biosimilars and biologics as of 2025

For further context on market positioning and peers, see Competitors Landscape of Procaps Group.

Procaps Group Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Procaps Group holds a top-tier position in global softgel and nutraceutical segments, with strong Latin American brand loyalty and growing US and global footprints; risks include currency devaluation in Brazil and Colombia and tightening regulatory/price controls that may pressure margins.

Industry Position

Procaps Group operations rank among leading softgel manufacturers, competing with Catalent and Lonza in specialized nutraceutical and OTC categories while maintaining market leadership in Latin America by prescription volume and brand loyalty.

Competitive Footprint

Procaps Group business model combines proprietary softgel technology Procaps with contract manufacturing services explained via integrated R&D, commercial packaging, and regional distribution, supporting expansion into the US, Europe and Asia.

Key Risks

Primary risks include currency devaluation impacting dollar-denominated debt servicing in Brazil and Colombia, regulatory tightening and price controls that could compress margins if operational efficiencies are not achieved.

Financial Sensitivities

As of 2025, foreign-exchange volatility remains a material factor for Procaps Group financial performance and structure; effective treasury management and local-currency revenue growth are critical to mitigate debt-service exposure.

Procaps Group's future outlook centers on digital transformation and smart manufacturing under the 'Procaps 5.0' roadmap, aiming to expand Funtrition gummies into Europe and Asia while improving yields and reducing waste.

Growth & Operational Priorities

Leadership targets AI-driven analytics to optimize batch yields and reduce waste by an estimated 12% by 2026, leveraging softgel technology Procaps and R&D to capture more of the $1.5 trillion global pharmaceutical market.

• Scale Funtrition gummy brand into Europe and Asia using established Procaps Group services and global logistics
• Invest in smart manufacturing to improve gross margins and lower cost per unit
• Focus on high-growth niches: personalized medicine, nutraceuticals, and specialized OTC delivery formats
• Mitigate currency and regulatory risks via localized production, hedging, and strict cost controls

For context on corporate purpose and governance that support these strategies, see Mission, Vision & Core Values of Procaps Group

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE